BRPI0506694A - análogos de peptìdeo-1 semelhante ao glucagon com longa duração de ação - Google Patents
análogos de peptìdeo-1 semelhante ao glucagon com longa duração de açãoInfo
- Publication number
- BRPI0506694A BRPI0506694A BRPI0506694-8A BRPI0506694A BRPI0506694A BR PI0506694 A BRPI0506694 A BR PI0506694A BR PI0506694 A BRPI0506694 A BR PI0506694A BR PI0506694 A BRPI0506694 A BR PI0506694A
- Authority
- BR
- Brazil
- Prior art keywords
- analogs
- peptide
- long
- acting glucagon
- glucagon
- Prior art date
Links
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 abstract 2
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical class C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 abstract 1
- 102000051325 Glucagon Human genes 0.000 abstract 1
- 108060003199 Glucagon Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
ANáLOGOS DE PEPTìDEO-1 SEMELHANTE AO GLUCAGON COM LONGA DURAçãO DE AçãO. Novos análogos de glp-1 tendo potência biológica aperfeiçoada, bem como atividade farmacológica estendida são descritos aqui. mais especificamente, a presente invenção se refere a análogos de glp-1 (28 ou 29 aa de comprimento) compreendendo de aminoácidos em um ou mais das sequintes posições: 8, 20, 27, 30 e 33.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53468204P | 2004-01-08 | 2004-01-08 | |
| US57007304P | 2004-05-12 | 2004-05-12 | |
| PCT/CA2005/000022 WO2005066207A1 (en) | 2004-01-08 | 2005-01-07 | Glucagon-like peptide-1 analogs with long duration of action |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0506694A true BRPI0506694A (pt) | 2007-05-02 |
Family
ID=34753021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0506694-8A BRPI0506694A (pt) | 2004-01-08 | 2005-01-07 | análogos de peptìdeo-1 semelhante ao glucagon com longa duração de ação |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7538185B2 (pt) |
| EP (1) | EP1709071A4 (pt) |
| JP (1) | JP2007537149A (pt) |
| AU (1) | AU2005203925A1 (pt) |
| BR (1) | BRPI0506694A (pt) |
| CA (1) | CA2552526A1 (pt) |
| WO (1) | WO2005066207A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2638800A1 (en) * | 2006-02-22 | 2007-09-07 | Merck & Co., Inc. | Oxyntomodulin derivatives |
| JP2009532422A (ja) * | 2006-04-03 | 2009-09-10 | ノボ・ノルデイスク・エー／エス | Ｇｌｐ−１ペプチドアゴニスト |
| WO2007139941A2 (en) | 2006-05-26 | 2007-12-06 | Amylin Pharmaceuticals, Inc. | Composition and methods for treatment of congestive heart failure |
| WO2008005527A2 (en) * | 2006-07-06 | 2008-01-10 | Amylin Pharmaceuticals, Inc. | Glucagon-like peptides and uses thereof |
| EP2222695A2 (en) * | 2007-12-11 | 2010-09-01 | F. Hoffmann-La Roche AG | Insulinotropic peptide synthesis using solid and solution phase combination techniques |
| BRPI0923853A2 (pt) * | 2008-12-29 | 2016-01-12 | Panacea Biotec Ltd | análogos de gpl-1 e usos dos mesmos. |
| JP5819946B2 (ja) * | 2010-05-17 | 2015-11-24 | ベータ ファーマシューティカルズ カンパニー リミテッド | 新規のグルカゴン様ペプチド類似体、組成物、および使用方法 |
| TWI622596B (zh) * | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| WO2017210100A1 (en) * | 2016-06-02 | 2017-12-07 | Indiana University Research And Technology Corporation | Glucagon-like peptide-1-t3 conjugates |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5118666A (en) * | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
| ATE164852T1 (de) | 1990-01-24 | 1998-04-15 | Douglas I Buckley | Glp-1-analoga verwendbar in der diabetesbehandlung |
| EP0969016A2 (en) | 1992-06-15 | 2000-01-05 | Scios Inc. | Glucagon-like peptide and insulinotropin derivates |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| US5981488A (en) * | 1997-03-31 | 1999-11-09 | Eli Lillly And Company | Glucagon-like peptide-1 analogs |
| WO1998043658A1 (en) * | 1997-03-31 | 1998-10-08 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
| WO1999043706A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Derivatives of glp-1 analogs |
| EP1056774A1 (en) | 1998-02-27 | 2000-12-06 | Novo Nordisk A/S | N-terminally truncated glp-1 derivatives |
| EP1992641A3 (en) * | 1998-12-07 | 2009-07-29 | Ipsen Pharma | GLP-1 analogues |
| CZ295044B6 (cs) * | 1998-12-07 | 2005-05-18 | Societe De Conseils De Recherches Et D'application | Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující |
| PL189664B1 (pl) | 1998-12-07 | 2005-09-30 | Sod Conseils Rech Applic | Nowy analog GLP-1, kompozycja farmaceutyczna go zawierająca oraz zastosowanie nowego analogu GLP-1 |
| AU2186900A (en) * | 1998-12-21 | 2000-07-12 | Eli Lilly And Company | Recombinant synthesis of beta-lipotropin and other peptides |
| JP4716641B2 (ja) | 2000-06-16 | 2011-07-06 | イーライ リリー アンド カンパニー | グルカゴン様ペプチド−１類似体 |
| AU3938402A (en) * | 2000-12-13 | 2002-06-24 | Lilly Co Eli | Chronic treatment regimen using glucagon-like insulinotropic peptides |
| ATE408414T1 (de) | 2001-07-31 | 2008-10-15 | Us Gov Health & Human Serv | Glp 1 exendin 4 peptidanaloga und deren verwendungen |
| AU2002322403A1 (en) | 2001-08-23 | 2003-03-10 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
| AU2003200839B2 (en) | 2002-01-08 | 2008-12-11 | Eli Lilly And Company | Extended glucagon-like peptide-1 analogs |
| WO2004029081A2 (en) * | 2002-09-25 | 2004-04-08 | Theratechnologies Inc. | Modified glp-1 peptides with increased biological potency |
-
2005
- 2005-01-07 AU AU2005203925A patent/AU2005203925A1/en not_active Abandoned
- 2005-01-07 US US11/031,851 patent/US7538185B2/en not_active Expired - Fee Related
- 2005-01-07 CA CA002552526A patent/CA2552526A1/en not_active Abandoned
- 2005-01-07 JP JP2006548056A patent/JP2007537149A/ja active Pending
- 2005-01-07 BR BRPI0506694-8A patent/BRPI0506694A/pt not_active IP Right Cessation
- 2005-01-07 WO PCT/CA2005/000022 patent/WO2005066207A1/en not_active Ceased
- 2005-01-07 EP EP05706387A patent/EP1709071A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2552526A1 (en) | 2005-07-21 |
| WO2005066207A8 (en) | 2006-02-02 |
| AU2005203925A1 (en) | 2005-07-21 |
| US20060014685A1 (en) | 2006-01-19 |
| EP1709071A1 (en) | 2006-10-11 |
| EP1709071A4 (en) | 2007-05-30 |
| WO2005066207A1 (en) | 2005-07-21 |
| JP2007537149A (ja) | 2007-12-20 |
| US7538185B2 (en) | 2009-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ514610A (en) | Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue | |
| WO2008155900A1 (ja) | 糖鎖付加glp-1ペプチド | |
| PA8525201A1 (es) | Tetrazolil-fenil acetamidas como activadores de la glucoquinasa | |
| AR072159A1 (es) | Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad | |
| BR9913932A (pt) | Uso de análogos de glp-1 no tratamento de derrame | |
| AR046877A1 (es) | Muteinas del factor de crecimiento de fibroblastos 21 | |
| AR109274A2 (es) | Composición que comprende uno o más fragmentos de péptido intestinal vasoactivo (vip) y su uso para la fabricación de un medicamento | |
| ATE482717T1 (de) | Peptid yy (pyy) zur behandlung von glukose stoffwechselkrankheiten | |
| ES2194720T3 (es) | Enzimas para el tratamiento de diabetes mellitus tipo i. | |
| SE9801992D0 (sv) | New 3-aryl-2-hydroxypropionic acid derivative I | |
| EA200100289A1 (ru) | Способ введения инсулинотропных пептидов | |
| UY31596A1 (es) | Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado | |
| DE602006020123D1 (de) | Glucagon-like-peptide-2- (glp-2-) analoga | |
| DK1180121T3 (da) | Langtidsvirkende insulinotrope peptider | |
| BRPI0413276B8 (pt) | derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica | |
| NO20063436L (no) | Intranasal administrasjon av glukose-regulerende peptider | |
| ATE466028T1 (de) | N-terminal veränderte glp-1 abkömmlinge | |
| BRPI0506694A (pt) | análogos de peptìdeo-1 semelhante ao glucagon com longa duração de ação | |
| AR050851A1 (es) | Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparacion y metodos de uso de los mismos | |
| UY27127A1 (es) | Derivados de la urea como antagonistas de integrin alfa-4 | |
| MX2020011007A (es) | Derivado de péptido-1 (glp-1) similar al glucagón acilado. | |
| AR042705A1 (es) | Derivados de pirazol modulador de ppar | |
| ES2061797T3 (es) | Mini-proinsulina, su preparacion y empleo. | |
| UY28080A1 (es) | Isómeros posicionales del ifn peg alfa 2a | |
| MX2008004734A (es) | Composicion rica en leucina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DA 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2205 DE 09/04/2013. |